Talk:Onyx Pharmaceuticals

Additions to Onyx page
My name is Adam Silverstein. I am with WCG, a public relations agency for Onyx. I have previously contributed suggested edits to the Onyx Pharmaceuticals page and have been grateful for the guidance received from the Wikipedia community. I would like to suggest edits to the sections of the Onyx page based on events that have occurred since October 2011.

 Onyx Pharmaceuticals  Inc. (nasdaq: ONXX) is a biopharmaceutical company headquartered in South San Francisco, California. The company develops and markets medicines for the treatment of cancer. Onyx was founded in 1992 by Frank McCormick Ph.D., FRS. In 2009, the company acquired Proteolix, Inc., a private biotechnology company. In January 2012, the company was named "the top biotechnology takeover target in 2012" through an industry survey. Onyx CEO Tony Coles has said Onyx likes it prospects as in independent company and is focused on bringing new therapies to patients.

Products and development
Sorafenib (co-developed and co-marketed by Bayer and Onyx as Nexavar ), is a drug approved for the treatment of advanced renal cell carcinoma, or advanced kidney cancer, and for the treatment of hepatocellular carcinoma, the most common form of liver cancer. Sorafenib is also being evaluated in additional types of cancer, including lung, thyroid and breast cancers.

In 2011, Bayer entered into an agreement with Onyx under which Onyx will receive a royalty on any future global net sales of regorafenib in oncology. Regorafenib is being studied in Phase 3 trials in demonstrated metastatic colorectal cancer, and gastrointestinal stromal tumors, a rare stomach cancer.

Onyx is conducting clinical trials investigating carfilzomib, a selective proteasome inhibitor that is being studied as a treatment for multiple myeloma. Clinical trials for carfilzomib include a pivotal Phase 2 clinical trial designed to seek accelerated approval in the U.S.

In January 2011, the U.S. Food and Drug Administration (FDA) granted carfilzomib fast-track status, allowing Onyx to initiate a rolling submission of its new drug application (NDA) for carfilzomib.Clinical trials for carfilzomib include a Phase 2 clinical trial designed to seek accelerated approval in the U.S. In December 2011, the FDA announced that it granted carfilzomib standard review, designation for its NDA. The PDUFA date, or FDA decision date, is July 27, 2012.

Onyx executive leadership team

 * N. Anthony (Tony) Coles, M.D.: President, Chief Executive Officer and Member of the Board
 * Matthew K. Fust: Executive Vice President and Chief Financial Officer
 * Juergen Lasowski, PH.D.: Executive Vice President, Corporate Development and Strategy
 * Ted W. Love, M.D.: Executive Vice President, Research & Development and Technical Operations
 * Helen I. Torley, M.B., CH.B., M.R.C.P.: Executive Vice President and Chief Commercial Officer
 * Kaye Foster-Cheek: Senior Vice President, Global Human Resources
 * Suzanne M. Shema, J.D.: Executive Vice President, General Counsel and Corporate Secretary
 * Julianna Wood: Vice President, Public Affairs

Onyx Board of Directors

 * N. Anthony (Tony) Coles, M.D.: President, Chief Executive Officer and Member of the Board
 * Paul Goddard PH.D.: Lead Director, Chairman and CEO Aryx Therapeutics Inc., Chairman, AP Pharma and Director, Adolor Corporation
 * Antonio J. Grillo-López, M.D.: Former Chairman, Neoplastic and Autoimmune Diseases Research Institute
 * Magnus Lundberg: Chief Executive Officer, Phadia
 * Corinne H. Nevinny: General Partner, LMNVC LLC
 * Bill Ringo: Executive Director, Sofinnova Ventures and Senior Advisor, Barclays Capital
 * Wendell Wierenga, PH.D: Executive Vice President, Research and Development, Santarus, Inc.
 * Thomas G. Wiggans: Former Chairman and CEO, Peplin, Inc., and Connetics Corporation

Edits to Onyx Page
I would ask Wikipedia community to please reach out to me if there are questions or concerns about suggested edits made to the Onyx page. Adam Silverstein (talk) 21:32, 23 March 2012 (UTC)

Proposed Updates to Onyx Page 7/29
My name is Adam Silverstein. I am with WCG, a public relations agency for Onyx Pharmaceuticals. I have previously contributed edits to this page (please see talk sections above for reference) appreciate the guidance I received from the Wikipedia community. On behalf of Onyx, I would like to open a conversation and suggest additional edits that reflect the FDA-approved indications and safety information for carfilzomib, sorafenib, and regorafenib.

I welcome feedback from any editor and thank you for your guidance. Adam Silverstein (talk) 20:31, 29 July 2013 (UTC)

Sorafenib
Current:

Sorafenib (co-developed and co-marketed by Bayer and Onyx under the trade name Nexavar), is a drug approved for the treatment of advanced renal cell carcinoma, or advanced kidney cancer, and for the treatment of hepatocellular carcinoma, the most common form of liver cancer. Sorafenib is also being evaluated in additional types of cancer, including lung, thyroid and breast cancers.

Revised: Sorafenib (co-developed and co-marketed by Bayer and Onyx under the trade name Nexavar), is a drug approved for the treatment of advanced renal cell carcinoma, or advanced kidney cancer, and for the treatment of hepatocellular carcinoma, the most common form of liver cancer. The most common adverse reactions (≥20%), which were considered to be related to sorafenib, are fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhea, anorexia, nausea and abdominal pain. Sorafenib is also being evaluated in additional types of cancer, including thyroid and breast cancers.
 * Adds information on areas where sorafenib is being studied
 * Adds information on adverse reactions

Carfilzomib
Current:

As of September 2011, Onyx is conducting clinical trials investigating carfilzomib, a selective proteasome inhibitor that is being studied as a treatment for multiple myeloma. Clinical trials for carfilzomib include a pivotal Phase 2 clinical trial designed to seek accelerated approval in the U.S. In January 2011, the U.S. Food and Drug Administration (FDA) granted carfilzomib fast-track status, allowing Onyx to initiate a rolling submission of its new drug application for carfilzomib. In December 2011, the FDA announced that it granted carfilzomib standard review, designation for its new drug application. The PDUFA date, or FDA decision date, is July 27, 2012.

Revised: Carfilzomib (marketed under the trade name Kyprolis) was approved by the FDA on June 20, 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy, and have demonstrated disease progression on or within 60 days of completion of the last therapy. Carfilzomib is also being evaluated in other stages of multiple myeloma. The most commonly reported adverse reactions (incidence ≥ 30%) are fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia.
 * Adds information on approved indications and adverse reactions

Regorafenib
Current:

In 2011, Bayer entered into an agreement with Onyx under which Onyx will receive a royalty on any future global net sales of regorafenib in oncology. Regorafenib is being studied in Phase 3 trials in demonstrated metastatic colorectal cancer, and gastrointestinal stromal tumors, a rare stomach cancer.

Revised: Regorafenib (marketed under the trade name Stivarga), is currently being studied as a potential treatment option in multiple tumor types. On 27 September, 2012, the FDA approved regorafenib for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild-type, an anti-EGFR therapy. On February 25, 2013, the FDA approved regorafenib in a second indication to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Regorafenib is a compound developed by Bayer. The most common adverse reactions (>/=20%) are asthenia/fatigue, HFSR, diarrhea, decreased appetite/food intake, hypertension, mucositis, dysphonia, and infection, pain (not otherwise specified), decreased weight, gastrointestinal and abdominal pain, rash, fever, and nausea. In 2011, Bayer entered into an agreement with Onyx under which Onyx will receive a 20 percent royalty on any future global net sales of regorafenib in oncology. Bayer and Onyx jointly promote Stivarga in the United States.
 * Adds details on approved indications